drug: galantamine |
|
|
| Clinical class....... | nootropic |
| Action.................... | reversible, competitive, acetyl cholinesterase inhibitor |
| CSA schedule | none |
| DEA number | none |
| Psychiatric uses | NA |
| Active metabolites | NA |
| Routes of administration | oral |
| Associated with (substance-related) |
disorders: none |
| Availability | prescription |
Also: galanthamine, Reminyl®
U.S. Preparations:
Razadyne™ (Janssen) FDA approved for treatment of mild to moderate dementia of the Alzheimer's type 6.22.2001U.S. Prescribing information
| Dose: | 4 mg. | 8 mg. | 12 mg. | ||||
| Color: | off-white | pink | orange-brown | ||||
| Shape: | circular biconvex | ||||||
| Type: | film-coated tablet | ||||||
| Imprint: |
Janssen |
||||||
| G4 | G8 | G12 | |||||
Razadyne™ ER (Janssen) FDA approved for treatment of mild to moderate dementia of the Alzheimer's type 12.22.2004
Preparations Outside U.S.:
- Nivalin